12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Other News

Pozen, Par Pharmaceutical neurology news

The U.S. District Court for the Eastern District of Texas granted a preliminary injunction to prevent Par from launching its generic version of migraine drug Treximet sumatriptan/naproxen. Pozen...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >